Newbury Pharmaceuticals Q4 Report: Bolstered business - Redeye

Redeye provides a research update following the Q4 report published by Newbury yesterday. We make some slight adjustments to our estimates for net sales and include the recent loan agreement in our model. However, we reiterate our fair value range with a base case valuation of SEK8.5 as we maintain a positive outlook on the case.

Länk till analysen i sin helhet: https://www.redeye.se/research/946550/newbury-pharmaceuticals-q4-report-bolstered-business?utm_source=finwire&utm_medium=RSS